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Introduction: Our objectives were to examine mononuclear cell gene expression profiles in patients with systemic
lupus erythematosus (SLE) and healthy controls and to compare subsets with and without atherosclerosis to
determine which genes’ expression is related to atherosclerosis in SLE.
Methods: Monocytes were obtained from 20 patients with SLE and 16 healthy controls and were in vitro-differentiated
into macrophages. Subjects also underwent laboratory and imaging studies to evaluate for subclinical atherosclerosis.
Whole-genome RNA expression microarray was performed, and gene expression was examined.
Results: Gene expression profiling was used to identify gene signatures that differentiated patients from controls and
individuals with and without atherosclerosis. In monocytes, 9 out of 20 patients with SLE had an interferon-inducible
signature compared with 2 out of 16 controls. By looking at gene expression during monocyte-to-macrophage
differentiation, we identified pathways which were differentially regulated between SLE and controls and identified
signatures based on relevant intracellular signaling molecules which could differentiate SLE patients with
atherosclerosis from controls. Among patients with SLE, we used a previously defined 344-gene atherosclerosis
signature in monocyte-to-macrophage differentiation to identify patient subgroups with and without atherosclerosis.
Interestingly, this signature further classified patients on the basis of the presence of SLE disease activity and cardiovascular
risk factors.
Conclusions: Many genes were differentially regulated during monocyte-to-macrophage differentiation in SLE patients
compared with controls. The expression of these genes in mononuclear cells is important in the pathogenesis of SLE,
and molecular profiling using gene expression can help stratify SLE patients who may be at risk for development of
atherosclerosis.* Correspondence: benjamin-korman@northwestern.edu
†Equal contributors
ˆDeceased
1Northwestern University Feinberg School of Medicine, 240 E Huron Street,
McGaw M-230, Chicago, IL 60611, USA
Full list of author information is available at the end of the article
© 2014 Korman et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Korman et al. Arthritis Research & Therapy 2014, 16:R147 Page 2 of 12
http://arthritis-research.com/content/16/4/R147Introduction
Systemic lupus erythematosus (SLE) is a chronic multisys-
tem autoimmune disease with a diverse array of clinical
manifestations. More recently, it has become evident that
SLE is associated with both accelerated atherosclerosis
and an increased risk of cardiovascular complications.
Women with SLE have a high prevalence of coronary
heart disease, and in some cohorts this figure is as high as
6% to 10% [1-4]. The estimated incidence of new cardio-
vascular events in patients with SLE is approximately 1.2%
to 1.5% per year, which represents a five- to six-fold age-
adjusted increased risk compared with women without
SLE, which is even more striking since it occurs in young
pre-menopausal women [5]. Although chronic inflamma-
tion is thought to be an important risk factor for these
manifestations and a number of cytokines (including
interferons) have been proposed as important in this
process, the exact pathogenesis of atherosclerosis in SLE
remains to be elucidated [6].
Monocytes recruited into tissues from peripheral
blood differentiate into macrophages, which are critical
in the pathogenesis of many diseases, including both
atherosclerosis and SLE [7]. Atherosclerosis has long
been associated with chronic inflammation, and previous
work has shown that monocytes and macrophages play
an important role in the development of atherosclerosis
[8,9]. Recent studies have shown that patients with SLE
have monocyte/macrophage defects involving surface
protein expression, cytokine production, and phagocytic
capacity, suggesting that monocytes and macrophages
are key players in the pathobiology of SLE [10].
RNA expression microarray has been previously used
to analyze mononuclear cells from patients with SLE
and has identified an interferon-inducible gene expres-
sion profile which is seen in a significant proportion of
patients with SLE and tends to correlate with more
severe disease manifestations [11-14]. Similar analyses
have been done in patients with coronary artery disease
and atherosclerosis and have found strong differential
expression of genes related to innate and adaptive
immunity, particularly those involved in leukocyte tran-
sendothelial migration [15-18].
There are dramatic changes in gene expression profiles
during monocyte-to-macrophage differentiation, inclu-
ding genes important in lipid metabolism and foam cell
function [19,20]. Furthermore, since monocytes differen-
tiate into macrophages as they egress from the circula-
tion into the inflammatory or atherosclerotic milieu, we
reasoned that comparing this process in patients with
SLE and controls might reveal differences that would
provide insights into the increased risk for atheroscle-
rosis seen in patients with SLE. To test this hypothesis,
we examined gene expression profiles in monocytes and
in vitro-differentiated macrophages in SLE patients andhealthy controls with and without subclinical athero-
sclerosis to look for differential expression patterns that
might help explain the increased coincidence of these
diseases.
Materials and methods
Peripheral blood was obtained from 36 females: 20 pa-
tients with SLE and 16 healthy controls. The institu-
tional review boards of Northwestern University and the
University of Illinois at Chicago approved the study, and
all participants gave written informed consent prior to
their involvement.
SLE patients and control subjects were selected from
the SOLVABLE study (Study of SLE Vascular and Bone
Long-term Endpoints, a prospective study assessing risk
for subclinical and clinical cardiovascular disease) on the
basis of having either evidence of atherosclerosis or no
evidence of atherosclerosis. All patients had a physician-
verified SLE diagnosis and met at least four American
College of Rheumatology (ACR) criteria for the clas-
sification of SLE. Controls were selected from the gene-
ral population and represent healthy women who were
matched to patients with SLE by age (±5 years), race/
ethnicity, and zip code of residence [21]. Controls did
not have evidence of SLE or other autoimmune disease.
At study visits, subjects filled out a questionnaire in
which they provided demographic, personal, and family
history and information about cardiovascular risk factors
and underwent routine physical examination and labo-
ratory tests. Patient subphenotypes were determined on
the basis of whether patients met each of the 11 ACR
classification criteria. Information on age, self-reported
race/ethnicity, smoking history, current estrogen use,
current aspirin use, and menopause status was obtained
from a questionnaire. (If indeterminate by questionnaire,
menopause was determined by follicle-stimulating hor-
mone status). Blood pressure was measured twice, and
the mean of the two measurements was used for
analysis. Height, weight, and waist/hip measurements
were obtained by using the protocol in the Multi-ethnic
Study of Atherosclerosis [22].
Laboratory tests were run on all patients and controls.
These included fasting lipids (total cholesterol, high-density
lipoprotein cholesterol (HDL-c), and triglyceride) and
fasting glucose measured in the Lipid Laboratory at the
University of Pittsburgh Graduate School of Public Health.
The Friedewald equation was used to estimate low-density
lipoprotein cholesterol (LDL-c) unless the triglyceride level
was more than 400 mg/dL, in which case LDL-c was mea-
sured directly. Plasma glucose levels were determined by
enzymatic assay, and plasma insulin levels were measured
by radioimmunoassay. C-reactive protein (CRP) was mea-
sured by using an immunonephelometric assay at the La-
boratory for Clinical Biochemistry Research at the University
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and double-stranded DNA (dsDNA) antibodies were mea-
sured by using the Crithidia luciliae method. dsDNA anti-
bodies were considered positive if the titer was at least 1:10.
All patients and controls were examined and validated
measures of SLE disease activity (Systemic Lupus Erythe-
matosus Disease Activity Index 2000, or SLEDAI-2K) as
well as disease damage (Systemic Lupus International
Collaborating Clinics/American College of Rheumatology
Damage Index, or SLICC/ACR-DI), which were completed
by trained physicians. The SLEDAI-2K and SLICC/ACR-DI
instruments were used to calculate disease activity and
damage, respectively [23,24]. Disease duration was calcu-
lated by using the date the subject fulfilled the 4th ACR
classification criteria for SLE for disease onset and the
study visit date as the end date. Participants provided in-
formation on corticosteroid treatment (current use and
duration of treatment) as well as current use of hydroxy-
chloroquine and immunosuppressants (which included
cyclophosphamide, azathioprine, methotrexate, mycophe-
nolate mofetil, cyclosporine, and tacrolimus). Renal disease
was defined as present if the subject had fulfilled ACR
classification criteria for SLE renal involvement (greater
than 0.5 gm/day or 3 or more proteinuria or the presence
of cellular casts or a combination of these) or had a renal
biopsy with evidence of World Health Organization class
IIb, III, IV, or V SLE nephritis. International Society of
Nephrology/Renal Pathology Society classification was not
used, because most renal biopsies were obtained prior to
its widespread use.
All 36 individuals underwent imaging evaluations of their
carotid arteries, coronary arteries, and aorta. For the pur-
pose of this study, we defined an atherosclerosis phenotype
by the presence of at least three of the following four
abnormalities on carotid ultrasound or electron beam
computed tomography (EBCT): a score of more than 0 on
the carotid plaque index, an intima-media thickness (IMT)
of greater than mean of the study group (0.67 mm), higher
coronary artery calcium (CAC) score (>10), or higher aorta
calcium (AC) score (>100) [25,26].
In the coronary arteries and aorta, EBCT scanning was
performed to measure vascular calcium by using an
Imatron C-150 Ultrafast CT scanner (General Electric
Medical Systems, South San Francisco, CA, USA). Cal-
cium scores were calculated with a densitometric program
available on the Imatron C-150 scanner by using the
Agatston method. The outcome measures used for ana-
lyses were dichotomized with a low CAC score of not
more than 10 and an AC score of not more than 100 and
a high CAC score of greater than 10 and an AC score of
greater than 100 signifying the presence of atherosclerosis
at these arterial beds [25,26].
Subclinical cardiovascular disease was measured in the
carotid arteries by B-mode ultrasound performed bytrained sonographers. Carotid ultrasound was performed,
and B-mode images of the right and left carotid artery,
carotid bifurcation, and the first centimeter of the internal
carotid were obtained in multiple planes and assessed for
plaque. Carotid ultrasound was completed in a single cen-
ter. Ultrasonographic measurements were performed by
using a Siemens Sequioa model C256 (Siemens, Munich,
Germany) equipped with a transducer 8 L5. Sonographers
scanned the right and left common carotid artery, carotid
bulb, and the first 1.5 cm of the internal and external ca-
rotid arteries. For each location, the sonographer imaged
the vessel in multiple planes. The sonographers scored the
ultrasound images for plaque in the distal common, carotid
bulb, and internal arteries. Plaque was defined as a distinct
area protruding into the vessel lumen with at least 50%
greater thickness than that found in surrounding areas.
IMT was measured by using specialized reading software
across 1-cm segments of both the right and left sides of
the near and far walls of the distal common carotid artery
and the far wall of the carotid bulb and internal carotid ar-
tery. The mean of all average IMT readings across the eight
sites was used for analysis. Reproducibility of IMT and
plaque was assessed in five women who underwent two
ultrasound examinations within 1 week. Each time, the
scanning was performed by a different sonographer, and
each scan was scored by two readers. Sonographers and
readers were trained as part of a reproducibility protocol
study in carotid duplex scanning [27].
Mononuclear cells were isolated from peripheral blood
of SLE patients and healthy controls, and then monocytes
were isolated and in vitro-differentiated into macrophages
[20]. Specifically, peripheral blood was drawn in tubes con-
taining citrate-phosphate-dextrose anti-coagulant solution
(Sigma-Aldrich, St. Louis, MO, USA). Mononuclear cells
were isolated by Histopaque-1077 density gradient centri-
fugation. Two different approaches were applied to isolate
monocytes. The first approach employed a Human CD14
Positive Selection Kit (StemCell Technologies, Vancouver,
BC, Canada), which isolates monocytes by directly binding
to anti-CD14 antibody-coupled magnetic beads. The cells
attached to the beads are immediately frozen in Trizol
at −70°C for future RNA isolation. Monocytes obtained
from this approach were more than 95% pure. To isolate
monocytes for in vitro differentiation into macrophages,
negative selection was employed (Human Monocyte En-
richment Kit Without CD16 Deletion) and resulted in
improved survival during differentiation. The mononu-
clear cells were incubated with an antibody cocktail
including antibodies to CD2, CD3, CD20, CD56, CD66b,
CD123, and glycophorin attached to magnetic beads,
which were employed because they resulted in higher pu-
rity. Cells positive for these markers were depleted, leaving
CD14+ monocytes from peripheral blood. The isolated
CD14+ cells were allowed to attach to plastic for 1 hour
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medium supplemented with 20% fetal bovine serum,
10 ng/mL macrophage colony-stimulating factor, 1 μg/mL
polymyxin-B, 100 U penicillin, and 100 mg/mL strepto-
mycin for 7 days at 37°C in 5% CO2.
RNA was extracted from monocytes and macrophages
by Trizol reagent (Invitrogen, Carlsbad, CA, USA). The
quality of RNA was determined by 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA), evaluated
by the RNA integrity number of at least 8.0 and the ratio
of 28 s and 18 s ribosomal RNA. RNA that passed quality
control was then used to create cDNA and biotinylated
cRNA by using an Illumina TotalPrep RNA Amplification
Kit (Illumina, San Diego, CA, USA). RNA was hybridized
to a Sentrix® Human-6 Expression BeadChip (Illumina) to
measure expression of more than 47,000 transcripts in
each sample.
Microarray data were normalized and corrected for
batch effect; we then performed significance analysis of
microarrays (SAM), multidimensional scaling (MDS) ana-
lysis, cluster analysis, and gene ontology (GO) analysis.
These analyses were performed first in monocytes and
macrophages separately and then during monocyte-to-
macrophage differentiation (the difference in expression
between an individual’s monocytes and macrophages). For
each of these groups, the comparisons included were (a)
SLE versus controls, (b) all individuals with versus without
an atherosclerosis phenotype, and (c) SLE patients with
versus without an atherosclerosis phenotype.
The microarray data were normalized by a quantile
normalization procedure by using the bioconductor pack-
age affy, and batch effect was corrected by using the
ComBat algorithm [28]. Cluster analysis was performed to
identify gene expression patterns by using CLUSTER and
TREEVIEW software. GO analysis was performed by
using the online application PANTHER (Protein Analysis
Through Evolutionary Relationships) [29]. The signi-
ficance of enrichment of differentially expressed genes
for each GO term was determined by the Bonferroni-
corrected chi-squared P value as the default setting in
PANTHER, whereas the significance of differential expres-
sion was determined by nominal P value of less than 0.05
from the t test and a fold change of greater than 2. MDS
analysis was performed to reveal the sample relation by
using global gene expression profiles. For monocyte-to-
macrophage differentiation analysis, we calculated fold
change for each probe as the ratio of macrophage
expression over monocyte expression from each pair of
monocyte-macrophage samples (from the same subject).
With these fold-change data, we excluded transcripts that
have average fold changes of less than 2 in both SLE pa-
tient and control groups. This filtering process resulted in
3,044 (out of 47,231) transcripts for data analysis. To de-
termine the fold-change difference between SLE patientsand controls for each of these 3,044 transcripts, we cal-
culated the P value by using the two-sample t test.
The microarray data are uploaded to Gene Expression
Omnibus with accession number GSE37356.
Results
Demographic, clinical, laboratory, and imaging results
Overall, there were few differences between baseline pa-
tient and control characteristics. Ten (50%) of 20 patients
with SLE and 10 (62.5%) of 16 controls had three of four
imaging abnormalities and were considered to have an
atherosclerosis phenotype. Patients with SLE were younger
than controls: means of 46.9 versus 52.8 years, P = 0.09
(not significant). No patients or controls had prior cardio-
vascular or cerebrovascular events attributable to athero-
sclerosis (two patients with SLE had prior stroke related to
antiphospholipid antibody syndrome). Further clinical,
demographic, and imaging data are detailed in Table 1.
Patients with SLE had long-standing disease with a mean
16.3-year duration and historically fulfilled a median of five
ACR classification criteria, 45% had anti-dsDNA anti-
bodies, and on average patients had some damage
(SLICC/ACR-DI mean of 2.15 ± 1.81). The majority of
patients (65%) were taking hydroxychloroquine, 30% were
on corticosteroids, and 40% were on immunosuppressive
agents (Table 1). With these medications, disease at the
time of the study visit was largely inactive or mild, and
SLEDAI scores averaged 4.2.
Gene expression profiles in monocytes and
monocyte-derived macrophages
The rank-based permutation method SAM did not identify
any discernible pattern of differential expression between
patients and controls or individuals with and without athe-
rosclerosis in either monocytes or monocyte-derived mac-
rophages (p >0.05 for all comparisons). However, striking
expression differences were evident between a subgroup of
SLE patients and controls from the primary monocyte data
(Figure 1A). The most prominent signature seen repre-
sents interferon-inducible genes in concordance with pre-
vious microarray data from patients with SLE [12,14]. The
interferon-inducible gene signature was prominent in nine
out of 20 cases and two out of 16 controls (odds ratio 5.7,
95% confidence interval (CI) 1.02, 32.0) (Figure 1A). One
case and one control individual with a marginal interferon
signature visually were considered not to have the signa-
ture, because they had less than 1.5 fold-change upregula-
tion of greater than half of the 53 interferon-inducible
genes. Of the nine SLE patients with the interferon signa-
ture, three had atherosclerosis; neither of the two controls
with the interferon signature had atherosclerosis. This sig-
nature was also present in macrophages, although it was
less prominent (Additional file 1). Another small subset of
patients with SLE (four out of 20 patients) did not have the
Table 1 Demographic, clinical, laboratory, medication, and imaging data from 20 systemic lupus erythematosus
patients and 16 controls
SLE mean ± SD Control mean ± SD p value
Age, years 46.9 ± 8.9 52.8 ± 11.0 0.09
Race, % who were Caucasian 75 80 0.98
Body mass index, kg/m2 27.7 ± 7.7 28.3 ± 4.9 0.79
Waist-hip ratio 0.85 ± 0.07 0.86 ± 0.08 0.69
Systolic blood pressure, mm Hg 117.4 ± 13.2 116.8 ± 14.4 0.88
Diastolic blood pressure, mm Hg 72.3 ± 9.0 71.8 ± 11.5 0.79
Current smoking, % 20 26.7 0.65
Diabetes, % 5 6 0.93
Family history of cardiovascular disease, % 10 7 0.74
Menopausal, % 45 53 0.64
Cardiovascular events 0 0 n/a
Total cholesterol, mg/dL 188.9 ± 51.9 218.9 ± 41.4 0.12
LDLc, mg/dL 101.5 ± 41.5 139.0 ± 8.7 0.04
Triglycerides, mg/dL 125.6 ± 99.9 101.0 ± 48.9 0.44
Glucose, mg/dL 98.4 ± 10.7 103.7 ± 13.9 0.27
Glomerular filtration rate, mL/min 80.7 ± 17.8 77.9 ± 18.8 0.65
C-reactive protein, mg/L 3.5 ± 3.6 3.8 ± 6.3 0.91
C3, mg/dL 101.5 ± 21.5
C4, mg/dL 20.3 ± 8.4
dsDNA (crithidia) level 66.3
Presence of carotid plaque 45 53 0.65
Higher CAC score (>10), % 35 33 0.92
Higher AC score (>100), % 50 47 0.85
Intima-media thickness (mean ± SD) 0.65 ± 0.14 0.71 ± 0.21 0.27
Atherosclerosis phenotype, % 50 62.5 0.47
SLEDAI-2 K 4.2 ± 4.3
SLICC/ACR-DI 2.2 ± 1.8
Disease duration, years 16.3 ± 8.2
Total ACR SLE classification criteria (median) 5
Corticosteroids 30 0 0.01
Hydroxychloroquine 65 0 0.00001
Immunosuppressants 40 0 0.002
Statins 35 0 0.03
Antihypertensives 45 25 0.09
Atherosclerosis phenotype was defined as the presence of at least three of the following four abnormalities on carotid ultrasound or electron beam computed
tomography: presence of carotid plaque, intima-media thickness greater than mean of the study group, high coronary calcium score of more than 10, or high aorta
calcium score of more than 100. Cardiovascular events were defined as myocardial infarction, coronary artery bypass surgery, coronary intervention, or cerebrovascular
events (transient ischemic attack or stroke) related to atherosclerotic disease. Validated measures of lupus disease activity and disease damage (SLEDAI-2 K and SLICC/
ACR-DI) were completed by trained physicians. The disease duration was calculated by using the date the subject fulfilled the 4th American College of Rheumatology
(ACR) classification criteria for lupus as onset date and study visit date as the end date. Renal disease was defined as being present if the subject had fulfilled ACR
classification criteria for lupus renal involvement (greater than 0.5 g/day, 3+ proteinuria, and/or the presence of cellular casts) or had a renal biopsy with evidence of
World Health Organization Class IIb, III, IV, or V lupus nephritis. The column on the right denotes percentages of patients meeting the various ACR clinical classification for
systemic lupus erythematosus (SLE). Double-stranded DNA (dsDNA) antibody level average includes only patients in whom these antibodies were present. Current
smoking was defined as individuals reporting use of one or more cigarettes daily, and no individuals reported prior smoking history. p values were calculated by using a
Student’s 7t-test. AC, aortic calcium; CAC, coronary artery calcium; LDLc, low-density lipoprotein cholesterol; SD, standard deviation; SLEDAI-2 K, Systemic Lupus
Erythematosus Disease Activity Index-2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
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Figure 1 Gene expression profiles in monocytes, macrophages, and monocyte-macrophage differentiation. (A,B) Gene expression
profiles using cluster analysis of 1,000 genes with highest coefficients of variation arranged by disease status and atherosclerosis phenotype.
Panel (A) shows expression patterns in monocytes, and panel (B) shows expression in macrophages. Above each heatmap is a legend: in the
upper section, the purple line denotes patients with systemic lupus erythematosus (SLE) and the orange line denotes healthy controls; in the
lower section, the blue line denotes individuals with an atherosclerosis phenotype (as defined in the methods section) and the maroon line
denotes individuals without the atherosclerosis phenotype. In the monocyte heatmap, note the presence of the interferon signature (denoted
by pink bar to right) in nine out of 20 SLE patients and the chemokine signature (brown bar) in three patients, both of which are very enriched
compared with controls. (C) Representative heatmap demonstrating downregulated signal transduction genes during monocyte-to-macrophage
differentiation after pairwise comparison of monocyte and macrophage expression in all 36 samples. Red (green) pixels indicate more (less) upregulation
of expression in macrophages compared with monocytes. (D) Histogram showing fold change (both upregulated and downregulated genes) among
genes involved in signal transduction pathway during monocyte-to-macrophage differentiation.
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of gene expression levels in a group of genes which encode
largely for chemokines (CXCL2, CCL3, CCL14, and
CCL20) and other soluble pro-inflammatory molecules:
tumor necrosis factor, interleukin-1 (IL-1), and IL-6. One of
four individuals with this chemokine signature had athero-
sclerosis. One individual had both the interferon and che-
mokine signatures. The remaining patients did not have
any gene signature that differentiated them from controls.
The full list of genes identified in the interferon and chemo-
kine gene signatures is detailed in Additional files 2 and 3.Monocyte-to-macrophage differentiation
When we compared each individual’s macrophage and
monocyte gene expression levels, we identified 3,044
genes with a macrophage over monocyte fold change with
a magnitude of greater than 2 in either the SLE group or
control group. A two-sample t test was performed to
determine the fold-change difference between SLE pa-
tients and controls. In this analysis, 270 transcripts (8.9%)
had more fold change during monocyte-to-macrophage
differentiation in SLE patients compared with controls
than would be expected by chance (p <0.05). Employing
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significant (p <0.001) enrichment of genes involved in sig-
nal transduction, immune system processes, carbohydrate
and lipid metabolic processes, and apoptosis differentially
regulated between the patients and controls (Table 2 and
Additional files 4 and 5).
Of the biologically relevant pathways observed, the signal
transduction pathway contained 147 differentially regulated
genes, the most of any pathway (Table 2). We looked at the
expression pattern of differentially expressed genes in this
pathway and found that there were clear differences be-
tween the SLE patients and the controls for genes that were
either upregulated or downregulated during macrophage
differentiation (Figure 1C, D). When cluster analysis was
performed with both upregulated and downregulated genes
in this pathway, SLE patients and controls were distinguish-
able. In the case of downregulated genes, the clusters were
able to differentiate 15 of the 20 patients from all of the 16
controls and five SLE patients of whom none had an athero-
sclerosis phenotype (Figure 1C). This pattern was not seen
when genes from other relevant pathways were analyzed.
Correlations with atherosclerosis
Unsupervised expression profiling in monocytes and mac-
rophages by using the 1,000 most differentially expressed
genes—those with the highest coefficient of variation (Cv)—
was unable to clearly distinguish individuals with and with-
out atherosclerosis. However, in monocytes from patients
with SLE, we demonstrated that patients with subclinical
atherosclerosis demonstrated substantial enrichment of
genes identified as associated with atherosclerosis based on
a previously described 344-gene signature used to differen-
tiate individuals with and without a substantial burden of
atherosclerosis [18]. A complete gene list for this signature
is detailed in Additional file 6. When used to look at all
individuals, this signature did not effectively delineateTable 2 Biologic processes in which genes associated with dif
differentiation
Biological process Genes in PANTHER database
Immune system process 2,628
Signal transduction 4,191
Apoptosis 966
B cell-mediated immunity 314
Lipid metabolic process 1,119
Intracellular signaling 1,568
Macrophage activation 305
Response to interferon-gamma 105
Induction of apoptosis 358
Carbohydrate metabolism 952
Complement activation 162
PANTHER, Protein Analysis Through Evolutionary Relationships.disease status or atherosclerosis status (Additional file 7).
We found that only 140 (4.6%) of 3,044 genes demon-
strated a P value of less than 0.05 when comparing the 19
participants with atherosclerosis with the 17 participants
without atherosclerosis (Additional file 3A). Among the 20
patients with SLE, we found 163 significant genes (5.3%)
with a P value of less than 0.05 between those with or
without atherosclerosis (Additional file 3B). Among the 16
controls, we found only 74 (2.4%) genes with a P value of
less than 0.05 between those with or without atheroscler-
osis (Additional file 3C). Of the genes identified in each of
these analyses, 11 (7.8%) out of 140, 22 (13.5%) out of 163
genes, and three (1.3%) out of 74 overlapped the previously
identified 344-gene atherosclerosis signature (Additional
file 3D). Upon hierarchical clustering analysis, these
differentially expressed genes did not differentiate any of
the groups by atherosclerosis status.
We found that the 344-gene atherosclerosis signature
hierarchically clustered patients with SLE into four clus-
ters based on disease activity and atherosclerosis status
(Figure 2 and Table 3). Cluster 1 had active SLE (defined
as SLEDAI ≥4) with minimal atherosclerosis and cardio-
vascular risk factors, cluster 2 had both active SLE and
atherosclerosis with more traditional cardiovascular risk
factors, cluster 3 had inactive SLE but substantial athe-
rosclerosis and traditional risk factors, and cluster 4 had
neither active SLE nor atherosclerosis but minimal car-
diovascular risk factors. Although the clustering first
separated individuals by disease activity (clusters 1 and 2
SLEDAI = 7.7 ± 4.7, clusters 3 and 4 SLEDAI = 2.3 ± 2.7),
within these clusters, clusters 2 and 3 were highly
enriched for atherosclerosis (eight of 11 patients had the
atherosclerosis phenotype) whereas clusters 1 and 4
were composed primarily of those without the athero-
sclerosis phenotype (two of nine patients had the athero-
sclerosis phenotype). When comparing the individualsferential expression during monocyte-to-macrophage
Observed Expected χ2 p value
127 52.93 9.98 × 10−22
147 84.41 5.75 × 10−13
45 19.45 2.18 × 10−7
21 6.32 2.49 × 10−6
46 22.54 4.59 × 10−6
58 31.58 6.08 × 10−6
19 6.14 1.97 × 10−5
10 2.11 6.83 × 10−5
19 7.21 1.58 × 10−4
35 19.17 5.33 × 10−4
11 3.26 5.43 × 10−4
Figure 2 Tree dendrogram derived from expression patterns of a previously described 344-gene atherosclerosis signature in systemic
lupus erythematosus (SLE) patients. Red boxes above an individual’s expression heatmap represent the presence of the atherosclerosis phenotype,
and a black box denotes its absence. Below each cluster, the individuals are stratified as having or not having active SLE (average SLEDAI of more than 4),
atherosclerosis phenotype (groups identified with the phenotype had greater than 70% of individuals with the atherosclerosis phenotype), SLE damage
(average SLICC/ACR-DI of more than 2), and traditional cardiovascular risk factors, including an average of at least one of the four risk factors of
hypertension, dyslipidemia, diabetes, and smoking. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR-DI, Systemic Lupus
International Collaborating Clinics/American College of Rheumatology Damage Index.
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without atherosclerosis (clusters 1 and 4), we found an
odds ratio of 9.3 (95% CI 1.2, 72.9) for this signature. We
also confirmed our findings by using a resampling-based
consensus clustering analysis with these genes (Additional
file 8).
Discussion
When we compared global gene expression of patients
with SLE and controls, we confirmed the importance of
type-1 interferon signature in monocytes. In addition,
we found that signal transduction, macrophage acti-
vation, response to interferon-gamma, and apoptosis
were differentially regulated during the process of monocyte-
to-macrophage differentiation.
About half of patients possess the interferon signature
and it appears to be associated with more severe disease,
including renal disease, which is a leading cause of mor-
bidity and mortality in SLE. Although previous work has
shown a mechanistic link between interferon-alpha and
atherosclerosis in SLE with interferon promoting ma-
crophage lipid uptake and foam cell formation [6], in-
terestingly, we did not see an association between this
signature and atherosclerosis and instead saw thatatherosclerosis was more common in individuals who did
not have an interferon signature with seven out of 11
without the interferon signature having atherosclerosis
versus two out of nine among individuals with the in-
terferon signature. Although the number of patients who
expressed a cytokine/chemokine expression signature
is small (four out of 20), the genes seen differentially
expressed in this subgroup suggest that alteration in
innate rather than adaptive immunity may play an impor-
tant role in the pathogenesis of SLE in a subset of patients.
In addition to having high disease activity, these indivi-
duals tended to have slightly shorter disease duration, and
none had an atherosclerosis phenotype (Table 3). Al-
though larger studies will be needed to confirm these
types of gene expression signature associations with cli-
nical data, if robust, they could potentially be used help
stratify patients’ risk for various disease manifestations or
risk of atherosclerosis.
Interestingly, we also identified lipid and carbohydrate
metabolism genes as differentially expressed in SLE pa-
tients compared with controls. One could hypothesize
that these genes’ expression may play a role in how these
cells participate in the processes of energy metabolism
and mitochondrial function during cellular differentiation
Table 3 Clinical characteristics of patients stratified by microarray clusters using 344-gene atherosclerosis signature
Microarray cluster 1 2 3 4
Demographics Age 45.8 ± 9.3 46.9 ± 5.4 49.0 ± 7.4 45.0 ± 13.0
Disease duration 13.6 ± 9.6 21.2 ± 3.31 17.3 ± 8.8 13.1 ± 9.2
SLE disease activity/damage SLEDAI-2 K 8.7 ± 6.4 7.0 ± 3.8 2.0 ± 3.1 2.7 ± 2.4
SLICC/ACR-DI 2.3 ± 2.3 4.0 ± 0.8 2.3 ± 1.6 0.7 ± 1.2
Renal disease 67.6% 100% 14.3% 33.3%
Atherosclerosis Atherosclerosis phenotype 0% 75.0% 71.0% 20.0%
Carotid intima-media thickness 0.53 0.69 0.72 0.59
Carotid plaque 0% 75.0% 57.1% 33.3%
Coronary artery calcium score 0 124 ± 85 349 ± 786 103 ± 252
Aortic calcium score 0 2,638 ± 3,261 828 ± 995 89 ± 149
Traditional cardiovascular risk factors 0 33.3% 25% 28.6% 66.7%
1 66.7% 25% 14.3% 16.7%
2 0% 25% 28.6% 16.7%
3 0% 25% 28.6% 0%
Average number of risk factors 0.7 1.5 1.6 0.5
Current medication use Steroids 33.3% 75.0% 28.6% 0.0%
Hydroxychloroquine 100% 75.0% 71.4% 33.3%
Immunosuppressants 33.3% 100% 28.6% 16.7%
Statins 0% 75.0% 28.6% 33.3%
Demographics, disease activity, and atherosclerosis measures are given in aggregate for each cluster. The four traditional cardiovascular risk factors assessed were
hypertension (defined as either systolic blood pressure of more than 140 mm Hg, diastolic blood pressure of more than 90 mm Hg or use of antihypertensives
and excluded individuals taking antihypertensives only for renal protective measures in the setting of systemic lupus erythematosus (SLE) nephritis), dyslipidemia
(defined as elevated total cholesterol or low-density lipoprotein according to Adult Treatment Panel III guidelines [30] or use of cholesterol lowering medication),
diabetes, and smoking. Definition and assessment of imaging parameters are described in the Materials and methods. SLEDAI-2 K, Systemic Lupus Erythematosus
Disease Activity Index-2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.
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that monocytes from patients with SLE upon entering
sites of inflammation or vascular injury may be pro-
grammed as they differentiate into macrophages with an
enhanced pathogenic potential to promote an atheroscle-
rosis phenotype.
Signal transduction genes during monocyte-to-macro-
phage differentiation were predictive of the presence or
absence of SLE; differentially downregulated genes were
able to identify 15 of 20 SLE patients from the controls
and five SLE patients who did not have atherosclerosis
(Figure 1B). Many of the genes differentially regulated
during monocyte-to-macrophage differentiation (down-
regulated genes include JAK2, STAT6, TLR8, and TLR2,
and upregulated genes include VEGFB, TGFB1, FN1,
IL-1R2, SCARB1, MSR1, and CD163) have been previously
reported in the pathogenesis of atherosclerosis [16,18,31,32].
Foamy macrophages in atherosclerotic plaques de-
monstrate both M1 and M2 markers, and similar trends
were observed during monocyte-to-macrophage diffe-
rentiation in SLE. Mechanistically, we found that JAK2
and STAT6 were suppressed to a greater degree during
monocyte-to-macrophage differentiation in patients with
SLE compared with controls, especially among patientswith atherosclerosis. JAK2 and STAT6 are both import-
ant in mediating M2 macrophage differentiation [33].
Expression of SOCS3, a JAK/STAT suppressor whose
deficiency leads to M1 differentiation, was also reduced
to a greater degree in patients with SLE. Furthermore,
IL15, which mediates its signal through STATs including
STAT6, was reduced more during monocyte-to-macro-
phage differentiation in patients with SLE, especially in
those with atherosclerosis. The JAK2 fold-change
expression was highly correlated with IL15 and IFITM1,
which supports the internal consistency of the data.
These results indicate that SLE patients’ monocytes favor
M1 rather than M2 differentiation compared with con-
trols. Furthermore, we found that, compared with con-
trols, patients with SLE had significantly increased levels
of vascular endothelial growth factor (VEGFB) which pro-
motes ischemic myocardial revascularization [31]. CD163,
an M2 marker, is highly expressed in atherosclerotic pla-
ques, whereas MSR1 is important in plaque formation
[32,34]. Patients with SLE therefore appear to have an
increased predilection for creating inflammatory M1
macrophages but also exhibit features associated with M2
differentiation which may contribute to the pathogenesis
of atherosclerosis.
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sample size. Although clinical heterogeneity in SLE is also a
concern, the SLE patients analyzed in this study were repre-
sentative of the larger SOLVABLE population of 165 individ-
uals who did not participate in this study in terms of clinical
parameters and medication use. Because of potential con-
founding from the relatively small sample size, we looked at
other variables, including medication usage, given the higher
use of immunomodulatory medications and statin medica-
tions in the patients with SLE. Although these differences
may contribute to some of the differences observed, we did
not find that individuals’ expression clustered by medication
use, and clustering based on medication status was not able
to identify patients with or without atherosclerosis (data not
shown). Given that patients on medication still had more
severe disease, the medications may have dampened these
patients’ inflammatory signatures.
Monocyte gene expression patterns of patients with SLE
and subclinical atherosclerosis were associated with a
344-gene signature previously reported as associated with
atherosclerosis (Figure 2) [18]. This signature includes pri-
marily immune and inflammatory genes, including six
Toll-like receptor genes, IL1B, IRAK3, and MAPK14, and
a number of genes involved in apoptosis and mobilization
of calcium. Strikingly, hierarchical clustering using this
gene signature divided patients into groups based on their
disease activity, and within these clusters, those with and
without an atherosclerosis phenotype. Although the
presence/absence of atherosclerosis was not absolute in
any group, the differences between groups were readily
apparent. Differences in patient demographics such as age
and disease duration were not statistically significant and
cannot fully account for the differences we saw between
clusters in terms of atherosclerosis. We did note a trend
(p = 0.14) for clusters 2 and 3 to have longer standing dis-
ease, and therefore without longitudinal follow-up of clus-
ters 1 and 4, it is difficult to say whether these individuals
will develop atherosclerosis at similar rates once they have
had longer disease duration. Cluster 2 (high disease acti-
vity, 100% renal disease, and abundant atherosclerosis),
like cluster 3 (low disease activity and abundant athero-
sclerosis), had substantial traditional cardiovascular risk
factors (diabetes, smoking, dyslipidemia, and hyperten-
sion). The data suggest that both disease activity and tra-
ditional risk factors appear to contribute to cardiovascular
risk in patients with SLE and raise the question of whether
these risks are additive. One potential confounder for this
gene expression pattern could be medication use, espe-
cially because immune modulating medications may affect
the expression of genes relevant to the signatures being
examined. For example, patients in cluster 2 were most
likely to be on steroids (P = 0.03) and immunosuppressants
(p = 0.004), which could affect their expression profile. Also,
the use of statins in patients with SLE may have had aneffect on gene expression and was likely to have had an
effect on progression (and possibly development) of athero-
sclerosis [35]. These data are intriguing and hypothesis-
generating but will need to be validated in a larger cohort
of patients than was possible in this pilot study.
Conclusions
Our data support the importance of the interferon-
inducible signature in SLE and suggest that gene expression
profiles in monocytes from patients with SLE are different
between individuals with high and low disease activity and
with and without atherosclerosis. The changes in expres-
sion seen during monocyte-to-macrophage differentiation
suggest that this process of differentiation may contribute
to disease pathogenesis, possibly by polarizing macrophages
toward classic M1 activation. Further studies may be
directed to determine whether factors present in SLE
serum, genetic predisposition, or stimuli such as the stress
response of oxidized lipid uptake might more clearly iden-
tify factors that promote the differentiation of pathogenic
macrophages in SLE.
Additional files
Additional file 1: Macrophage Interferon Signature. Heatmap of
limited interferon signature identified in in vitro-differentiated
macrophages is shown. SLE, systemic lupus erythematosus.
Additional file 2: Interferon gene signature. Expression values for
each of the 53 interferon-inducible genes identified are shown.
Additional file 3: Monocyte-to-macrophage differentiation. Genes
differentially expressed during monocyte-to-macrophage differentiation
are shown.
Additional file 4: Gene networks. Significant gene interaction
networks were determined by using pathway analysis performed by
using Ingenuity Pathways Analysis (IPA). GO, gene ontology; PANTHER,
Protein Analysis Through Evolutionary Relationships.
Additional file 5: Gene ontology (GO) term breakdowns. Heatmaps
derived from genes representing significant GO terms for all systemic
lupus erythematosus (SLE) cases and controls are shown.
Additional file 6: Three hundred forty-four-gene atherosclerosis
signature. Gene list for previously defined 344-gene atherosclerosis gene
signature is shown.
Additional file 7: Three hundred forty-four-gene atherosclerosis
signature. Heatmap demonstrates previously described 344-atherosclerosis
gene signature in all systemic lupus erythematosus (SLE) cases and controls.
Additional file 8: Consensus clustering. Resampling-based consensus
clustering analysis for 344-gene atherosclerosis signature is shown.
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